Richard Traynor
Corporate Secretary at CERTARA, INC.
Net worth: 3 M $ as of 30/05/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| William Feehery | M | 54 |
LA-SER Europe Ltd.
 LA-SER Europe Ltd. Pharmaceuticals: MajorHealth Technology LA-SER is a strongly science driven late-phase company with offices in 7 countries (UK, France, Germany, Spain, Italy, Canada and Morocco) encompassing a team of 150 specialists in late-phase clinical research. They cover a full range of late-phase services from observational studies, cohorts, registries, case-control studies, surveys, electronic health care database studies, pragmatic trials, they excel in risk/benefit management, effectiveness/relative effectiveness studies, and strategic consulting for drug value assessment. A truly unique feature is their in-depth understanding & knowledge of the process of drug value assessment, and of the methods, paradigms & modus operandi of regulatory decision-making bodies & agencies in several countries. Originally brought to the company by the founders of the company, this in-depth network knowledge is now shared by a large number of their senior staff. They can therefore provide remarkable insight into what evidence is required to grant market authorisation & reimbursement, for new drugs across different European countries & North America.
Certara USA, Inc.
 Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | 5 years |
| Michael Schemick | M | 50 |
Certara Holdco, Inc.
 Certara Holdco, Inc. Miscellaneous Commercial ServicesCommercial Services Certara Holdco, Inc. operates as holding company whose subsidiary provides decision support technology and consulting services for optimizing drug development and improving health outcomes. The company is headquartered in DE.
Certara UK Holdings Ltd.
 Certara UK Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Certara, Inc., Certara UK Holdings Ltd. is a company that develops drug therapies. The company is based in London, UK. Certara UK Holdings was founded in 2004.
LA-SER Europe Ltd.
LA-SER Europe Ltd. Pharmaceuticals: MajorHealth Technology LA-SER is a strongly science driven late-phase company with offices in 7 countries (UK, France, Germany, Spain, Italy, Canada and Morocco) encompassing a team of 150 specialists in late-phase clinical research. They cover a full range of late-phase services from observational studies, cohorts, registries, case-control studies, surveys, electronic health care database studies, pragmatic trials, they excel in risk/benefit management, effectiveness/relative effectiveness studies, and strategic consulting for drug value assessment. A truly unique feature is their in-depth understanding & knowledge of the process of drug value assessment, and of the methods, paradigms & modus operandi of regulatory decision-making bodies & agencies in several countries. Originally brought to the company by the founders of the company, this in-depth network knowledge is now shared by a large number of their senior staff. They can therefore provide remarkable insight into what evidence is required to grant market authorisation & reimbursement, for new drugs across different European countries & North America.
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | 10 years |
| Rosemary Crane | F | 64 |
Edge Therapeutics, Inc.
 Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 5 years |
| James Cashman | M | 70 |
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | 6 years |
| Mason Slaine | M | 71 |
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | 6 years |
| Matthew Walsh | M | 57 |
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | 7 years |
| Ethan Waxman | M | 35 |
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | 4 years |
| Stephen McLean | M | 66 |
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | 11 years |
| Richard James Wilson | M | 53 |
Certara UK Holdings Ltd.
Certara UK Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Certara, Inc., Certara UK Holdings Ltd. is a company that develops drug therapies. The company is based in London, UK. Certara UK Holdings was founded in 2004.
LA-SER Europe Ltd.
LA-SER Europe Ltd. Pharmaceuticals: MajorHealth Technology LA-SER is a strongly science driven late-phase company with offices in 7 countries (UK, France, Germany, Spain, Italy, Canada and Morocco) encompassing a team of 150 specialists in late-phase clinical research. They cover a full range of late-phase services from observational studies, cohorts, registries, case-control studies, surveys, electronic health care database studies, pragmatic trials, they excel in risk/benefit management, effectiveness/relative effectiveness studies, and strategic consulting for drug value assessment. A truly unique feature is their in-depth understanding & knowledge of the process of drug value assessment, and of the methods, paradigms & modus operandi of regulatory decision-making bodies & agencies in several countries. Originally brought to the company by the founders of the company, this in-depth network knowledge is now shared by a large number of their senior staff. They can therefore provide remarkable insight into what evidence is required to grant market authorisation & reimbursement, for new drugs across different European countries & North America. | 8 years |
| Ellen Leinfuss | F | - |
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | - |
| Leif Pedersen | M | 60 | 4 years | |
| Nancy Killefer | F | 69 | 3 years | |
| Amin Rostami-Hodjegan | M | - |
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | - |
| Joseph Woody | M | 58 |
LifeCell Corp.
 LifeCell Corp. BiotechnologyHealth Technology LifeCell Corp. develops and markets tissue repair products. The firm focuses on reconstructive, urogynecologic and orthopedic surgical procedures. Its products include alloderm, strattice, graft jacket, allocraftdbm and repliform. The company was founded in 1986 and is headquartered in Branchburg, NJ. | 11 years |
| David Spaight | M | 65 | 2 years | |
| Eran Broshy | M | 65 | 2 years | |
| Cynthia Collins | F | 65 | 3 years | |
| James Carlson | M | 72 |
LifeCell Corp.
LifeCell Corp. BiotechnologyHealth Technology LifeCell Corp. develops and markets tissue repair products. The firm focuses on reconstructive, urogynecologic and orthopedic surgical procedures. Its products include alloderm, strattice, graft jacket, allocraftdbm and repliform. The company was founded in 1986 and is headquartered in Branchburg, NJ. | 11 years |
| Edmundo Manuel Muniz | M | 68 |
Certara UK Holdings Ltd.
Certara UK Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Certara, Inc., Certara UK Holdings Ltd. is a company that develops drug therapies. The company is based in London, UK. Certara UK Holdings was founded in 2004. | 7 years |
| John Gallagher | M | 51 | 1 years | |
| Mark Hovde | M | 67 |
Certara USA, Inc.
Certara USA, Inc. Miscellaneous Commercial ServicesCommercial Services Certara USA, Inc. provides drug development consultancy solutions. It offers benefits of modeling and simulation, label optimization, pediatric drug development, orphan drug development, clinical trial outcomes databases, and therapeutic areas. The company was founded in 2008 and is headquartered in Princeton, NJ. | - |
| Jaap Mandema | M | - | - | |
| Thomas Casey | M | 61 |
LifeCell Corp.
LifeCell Corp. BiotechnologyHealth Technology LifeCell Corp. develops and markets tissue repair products. The firm focuses on reconstructive, urogynecologic and orthopedic surgical procedures. Its products include alloderm, strattice, graft jacket, allocraftdbm and repliform. The company was founded in 1986 and is headquartered in Branchburg, NJ. | 10 years |
| Thomas Kerbusch | M | 52 |
LA-SER Europe Ltd.
LA-SER Europe Ltd. Pharmaceuticals: MajorHealth Technology LA-SER is a strongly science driven late-phase company with offices in 7 countries (UK, France, Germany, Spain, Italy, Canada and Morocco) encompassing a team of 150 specialists in late-phase clinical research. They cover a full range of late-phase services from observational studies, cohorts, registries, case-control studies, surveys, electronic health care database studies, pragmatic trials, they excel in risk/benefit management, effectiveness/relative effectiveness studies, and strategic consulting for drug value assessment. A truly unique feature is their in-depth understanding & knowledge of the process of drug value assessment, and of the methods, paradigms & modus operandi of regulatory decision-making bodies & agencies in several countries. Originally brought to the company by the founders of the company, this in-depth network knowledge is now shared by a large number of their senior staff. They can therefore provide remarkable insight into what evidence is required to grant market authorisation & reimbursement, for new drugs across different European countries & North America. | - |
| Robert Aspbury | M | 53 | 4 years | |
| Patrick Smith | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Lisa Colleran | F | 66 |
LifeCell Corp.
LifeCell Corp. BiotechnologyHealth Technology LifeCell Corp. develops and markets tissue repair products. The firm focuses on reconstructive, urogynecologic and orthopedic surgical procedures. Its products include alloderm, strattice, graft jacket, allocraftdbm and repliform. The company was founded in 1986 and is headquartered in Branchburg, NJ. | 11 years |
| Jim Zink | M | - |
University of Notre Dame
| 5 years |
| Carol Gallagher | M | 59 | 1 years | |
| Michael J. Messaglia | M | - |
University of Notre Dame
| 7 years |
| Sherilyn McCoy | F | 65 | 3 years | |
| Eric Liu | M | 47 | 5 years | |
| Ronald A. Matricaria | M | 81 |
LifeCell Corp.
LifeCell Corp. BiotechnologyHealth Technology LifeCell Corp. develops and markets tissue repair products. The firm focuses on reconstructive, urogynecologic and orthopedic surgical procedures. Its products include alloderm, strattice, graft jacket, allocraftdbm and repliform. The company was founded in 1986 and is headquartered in Branchburg, NJ. | - |
| Victor Cuciniello | M | - |
University of Notre Dame
| 5 years |
| Brian T. Busenlehner | M | 49 |
LifeCell Corp.
LifeCell Corp. BiotechnologyHealth Technology LifeCell Corp. develops and markets tissue repair products. The firm focuses on reconstructive, urogynecologic and orthopedic surgical procedures. Its products include alloderm, strattice, graft jacket, allocraftdbm and repliform. The company was founded in 1986 and is headquartered in Branchburg, NJ. | - |
| David Kovacs | M | - |
University of Notre Dame
| 5 years |
| Patrick D. Buckley | M | - |
University of Notre Dame
| 4 years |
| Kimberly Ryan | F | - |
University of Notre Dame
| 4 years |
| Erik Staffeldt | M | 52 |
University of Notre Dame
| 4 years |
| Brian A. Dominic | M | - |
University of Notre Dame
| 4 years |
| R. Meyer | M | - |
University of Notre Dame
| 4 years |
| Melinda Lindland | F | - |
University of Notre Dame
| 4 years |
| Adam K. Spahn | M | - |
University of Notre Dame
| 4 years |
| Eric Hart | M | 57 |
LifeCell Corp.
LifeCell Corp. BiotechnologyHealth Technology LifeCell Corp. develops and markets tissue repair products. The firm focuses on reconstructive, urogynecologic and orthopedic surgical procedures. Its products include alloderm, strattice, graft jacket, allocraftdbm and repliform. The company was founded in 1986 and is headquartered in Branchburg, NJ. | 1 years |
| Jean Lucien Joseph | M | - |
University of Notre Dame
| 4 years |
| Jim E. Sexton | M | - |
University of Notre Dame
| 4 years |
| Matthew K. Maher | M | - |
University of Notre Dame
| 4 years |
| Derrick Mayes | M | 50 |
University of Notre Dame
| 4 years |
| Jeff Bocan | M | - |
University of Notre Dame
| 4 years |
| Lou Rassey | M | 50 |
University of Notre Dame
| 3 years |
| Darin B. Schmalz | M | - |
University of Notre Dame
| 4 years |
| Thomas Patrick Hogan | M | - |
University of Notre Dame
| 4 years |
| Brian Smith | M | - |
University of Notre Dame
| 2 years |
| Michael Blum | M | - |
University of Notre Dame
| 3 years |
| Joelle Kellam | F | - |
University of Notre Dame
| 4 years |
| Scott Voulgaris | M | - |
University of Notre Dame
| - |
| Brendan Teehan | M | 56 |
University of Notre Dame
| 4 years |
| Mark Flaharty | M | 56 |
University of Notre Dame
| 4 years |
| Desney Tan | M | 48 |
University of Notre Dame
| 4 years |
| Maverick Wong | F | - |
University of Notre Dame
| 4 years |
| Dean S. Wikenheiser | M | - |
University of Notre Dame
| 4 years |
| Bill Mordan | M | - |
University of Notre Dame
| 4 years |
| Richard Schneider | M | - |
University of Notre Dame
| 4 years |
| Seth David Miller | M | - |
University of Notre Dame
| 4 years |
| John S. Evans | M | - |
University of Notre Dame
| 4 years |
| Joseph S. Burkhart | M | - |
University of Notre Dame
| 4 years |
| Kathleen M. Kenney | F | - |
University of Notre Dame
| 3 years |
| John Dellafiora | M | - |
University of Notre Dame
| 4 years |
| Donna Snider | F | - |
University of Notre Dame
| 4 years |
| John Arlotta | M | 74 |
University of Notre Dame
| 4 years |
| Andy W. Hubregsen | M | - |
University of Notre Dame
| 2 years |
| Michael W. Shrekgast | M | - |
University of Notre Dame
| 4 years |
| Michael J. Caputo | M | - |
University of Notre Dame
| 4 years |
| Chris Zepf | M | 52 |
University of Notre Dame
| 4 years |
| Steve Wilkes | M | - |
University of Notre Dame
| 2 years |
| Pierre Chapdelaine | M | - |
University of Notre Dame
| 2 years |
| Brian P. Gallagher | M | - |
University of Notre Dame
| 4 years |
| Kevin Perry | M | - |
University of Notre Dame
| 4 years |
| Tim Kuehl | M | - |
University of Notre Dame
| 4 years |
| Larry Playford | M | - |
University of Notre Dame
| 4 years |
| Tom Michael Roderick | M | - |
University of Notre Dame
| 4 years |
| Kathryn Cavanaugh | F | 50 |
University of Notre Dame
| 4 years |
| Thomas Mullarkey | M | - |
University of Notre Dame
| 4 years |
| Benjamin T. Harries | M | - |
University of Notre Dame
| 4 years |
| Brian Pears | M | - |
University of Notre Dame
| 4 years |
| Brian Evans | M | 56 |
University of Notre Dame
| 4 years |
| Sean T. Klimczak | M | 47 |
University of Notre Dame
| 4 years |
| Jeremy Joseph Joyce | M | - |
University of Notre Dame
| 4 years |
| Brian Mulhern | M | - |
University of Notre Dame
| 3 years |
| Shawn Foley | M | - |
University of Notre Dame
| 4 years |
| Mike Sullivan | M | - |
University of Notre Dame
| 3 years |
| Thomas Monroe | M | - |
University of Notre Dame
| 2 years |
| Kevin Whelan | M | - |
University of Notre Dame
| 4 years |
| Mark T. Bettencourt | M | - |
University of Notre Dame
| 4 years |
| M. Phillips | M | - |
University of Notre Dame
| 4 years |
| Bridget Weishaar | F | - |
University of Notre Dame
| 4 years |
| Anita L. Chapdelaine | F | - |
University of Notre Dame
| 4 years |
| Michael Rost | M | 49 |
University of Notre Dame
| 4 years |
| Brian Staff | M | - |
University of Notre Dame
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 96 | 96.97% |
| United Kingdom | 5 | 5.05% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Richard Traynor
- Personal Network
